Implant Sciences' Quantum Sniffer QS-H150 Deployed at Major International Bank in Middle East

Marketwired

WILMINGTON, MA--(Marketwire -01/19/12)- Continuing its strategic sales success with commercial customers, Implant Sciences Corporation (OTCQB: IMSC.PK - News) (Pinksheets: IMSC.PK - News), a high technology supplier of systems and sensors for homeland security markets, announced today it has recently delivered units of its portable explosives trace detector, the Quantum Sniffer™ QS-H150, to a major Middle Eastern bank.

The Middle East is a key growth region for Implant Sciences, where the Company has had recent success selling explosives trace detection units for both commercial and military deployments. This new customer confirms the increasing commitment businesses have to the protection of their employees, clients, and infrastructure.

Glenn D. Bolduc, President and CEO of Implant Sciences, commented, "The acceptance and demand for our Quantum Sniffer units in what is one of the most security-oriented regions of the world, is a testament to the value our devices offer to users. Knowledgeable customers, such as these, select our devices because of proven real-world capabilities. Of the many options for explosives detection available on the market today, the Quantum Sniffer continues to emerge as a top choice of security experts globally."

About the Quantum Sniffer™ QS-H150

The QS-H150 is a handheld explosives trace detector that uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, and homemade explosives. The QS-H150 uses no radioactive materials and features a low-maintenance design that is self-calibrating and self-clearing, providing very high levels of operational availability.

About the Quantum Sniffer™ QS-B220

The QS-B220, introduced in May 2011, is a benchtop explosives and narcotics trace detector that uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, and homemade explosives, plus narcotic substances. The QS-B220 continues the Implant Sciences tradition of freedom from radioactive materials, low total cost of ownership, and high operational availability.

About Implant Sciences

Implant Sciences develops, manufactures, and sells sophisticated sensors and systems for Security, Safety, and Defense (SS&D) markets. The Company has developed innovative proprietary technologies used in its explosives and narcotics trace detection systems, which ship to a growing number of locations domestically and internationally. Implant Sciences products have been deployed in a wide range of security environments including airports, subways, railways, cargo facilities, nuclear power plants, police departments, military units, government buildings, and financial institutions. The QS-H150 and QS-B220 are Department of Homeland Security (DHS) Qualified Anti-Terrorism Technologies under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act). For further details on the Company and its products, please visit the Company's website at www.implantsciences.com.

Safe Harbor Statement

This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that our explosives detection products and technologies (including any new products we may develop) may not be accepted by the Transportation Security Administration or by other U.S. or foreign government and law enforcement agencies or commercial consumers of security products; economic, political and other risks associated with international sales and operations could adversely affect our sales; our business is subject to intense competition and rapid technological change; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including our most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.

Contact:

Implant Sciences Corporation
Company
Glenn Bolduc
CEO
978-752-1700
Email Contact
or
Investor
Laurel Moody
646-810-0608
Email Contact

View Comments